SCHEMBL5134971

SCHEMBL5134971

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CC)Cc1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.46
TSHR P16473 6/20 0.43
KDM4E B2RXH2 6/20 0.39
ALDH1A1 P00352 6/20 0.39
HPGD P15428 6/20 0.39
HSD17B10 Q99714 6/20 0.39
CYP3A4 P08684 5/20 0.39
HSD11B1 P28845 2/20 0.38
MMP1 P03956 1/20 0.37
MMP13 P45452 1/20 0.37
NR1H3 Q13133 1/20 0.37
BCHE P06276 3/20 0.36
HDAC1 Q13547 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5072370 0.95 C5AR1 (0.47) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5136574 0.93 C5AR1 (0.46) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5136220 0.93 C5AR1 (0.46) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5137883 0.92 TSHR (0.48) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5137312 0.91 C5AR1 (0.48) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135643 0.91 C5AR1 (0.48) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135469 0.90 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5138064 0.90 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5072228 0.89 C5AR1 (0.46) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5136656 0.89 C5AR1 (0.46) C5AR1TSHRKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed